Neuromuscular Junction

Disorders
Dr.Mohammed Radhi Radeef
Neuromuscular Junction Disorders
 Fre synaptic nerve terminal

La mb e rt-E a Ibo □ s pi
die me (antibody)
Ca1+ S^raaptk- Amkiagtycot ide
clianoel I vesicle ^ antibiotics
Ca
1+ ^ o°o
°° a +
“0°0 O Botulism
Vo°os° o
(tomn)
My a ith e-nn gravis
(antibody)
Clinical findings
Examination
Tensilon test: Before (left); After (right)
Investigation studies
 Repetitive nerve stimulation

A, Endplate potential
FIGURE 2-3 (EPP) amplitude is reduced in myasthenia
gravis (MG), narrowing the safety factor of
neuromuscular transmission. With repeated
stimulations the EPP amplitude falls below threshold for muscle fiber
activation—neuromuscular transmission failure. B. When a critical
number of EPPs fail, a decremental response is seen on repetitive
nerve stimulation studies.
 NDC 47781-335-30

) Pyridostigmine
Bromide
EXTENDED-RELEASE
TABLETS
CAUTION JXTRtUtl*
ucxsruflc
scNsmvt DO HOT
WCKOVf _ (
DC1HCCANT. CtOSC T***'1,

30 Tablets
^Alv/ogen
■■■II

MabThera®
Rituximab
500mg/50ml
Q 1 vial of 50 ml of concentrate
for
solution for infusion \ /
 Fre synaptic nerve terminal

La mb e rt-E a Ibo □ s pi
die me (antibody)
Ca1+ S^raaptk- Amkiagtycot ide
clianoel I vesiclea ^ antibiotics
Ca
1+ ^ o°o
°° “+° 0 0 O
Botulism
Vo°o ° o
s
(tomn)
My a ith e-nn gravis
(antibody)
Clinical finding